| P50 | author | Jolanta B Zawilska | Q89104874 |
| P2093 | author name string | Piotr Adamowicz | |
| | Monika Kacela | |
| P2860 | cites work | Serotonin syndrome | Q94024529 |
| | Changes in neuronal activity in rat primary cortical cultures induced by illicit drugs and new psychoactive substances (NPS) following prolonged exposure and washout to mimic human exposure scenarios | Q91948144 |
| | Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005-2017 | Q92184134 |
| | Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe | Q92504062 |
| | Fatalities related to new psychoactive substances in Singapore-A case series | Q92506312 |
| | Simultaneous analysis of 2Cs, 25-NBOHs, 25-NBOMes and LSD in seized exhibits using liquid chromatography-tandem mass spectrometry: A targeted approach | Q92987979 |
| | Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats | Q93118570 |
| | MS-Based Molecular Networking of Designer Drugs as an Approach for the Detection of Unknown Derivatives for Forensic and Doping Applications: A Case of NBOMe Derivatives | Q93126601 |
| | Abuse potential of 2-(4-iodo-2, 5-dimethoxyphenyl)N-(2-methoxybenzyl)ethanamine (25INBOMe); in vivo and ex vivo approaches | Q91623439 |
| | A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents | Q91675489 |
| | Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors | Q91811794 |
| | 25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro | Q91927918 |
| | High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens | Q37630040 |
| | 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. | Q37633498 |
| | Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death | Q37672302 |
| | 2C-I-NBOMe, an "N-bomb" that kills with "Smiles". Toxicological and legislative aspects | Q38208426 |
| | Prevalence of use and acute toxicity associated with the use of NBOMe drugs | Q38346439 |
| | Fatal Intoxications with 25B-NBOMe and 25I-NBOMe in Indiana During 2014. | Q38588257 |
| | A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State | Q38588258 |
| | New Drugs of Abuse and Withdrawal Syndromes | Q38614202 |
| | Experimental Study on the Postmortem Redistribution of the Substituted Phenethylamine, 25B-NBOMe | Q38712647 |
| | NBOMe hallucinogenic drug exposures reported to the Danish Poison Information Centre | Q38752840 |
| | Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens | Q39093171 |
| | Non-traumatic rhabdomyolysis: Background, laboratory features, and acute clinical management. | Q39149853 |
| | 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry | Q39569585 |
| | Identification of novel psychoactive substances 25B-NBOMe and 4-CMC in biological material using HPLC-Q-TOF-MS and their quantification in blood using UPLC-MS/MS in case of severe intoxications | Q39591988 |
| | 25I-NBOMe related death in Australia: a case report | Q41278661 |
| | An evaluation of 25B-, 25C-, 25D-, 25H-, 25I- and 25T2-NBOMe via LC-MS-MS: method validation and analyte stability | Q43407752 |
| | An investigation of the stability of emerging new psychoactive substances | Q44276254 |
| | The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats | Q44508158 |
| | Severe poisoning after self-reported use of 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, a novel substituted amphetamine: a case series | Q45013644 |
| | Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex | Q45056353 |
| | Effect of Hallucinogens on Unconditioned Behavior | Q45279141 |
| | Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and | Q46450715 |
| | Retrospective demonstration of 25I-NBOMe acute poisoning using hair analysis | Q47181383 |
| | A Validated Method for the Detection of 32 Bath Salts in Oral Fluid | Q47686894 |
| | Death after 25C-NBOMe and 25H-NBOMe consumption | Q47891412 |
| | Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometry | Q47974432 |
| | Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases | Q48069477 |
| | Detection of 25C-NBOMe in Three Related Cases | Q48721685 |
| | Metabolic Fate of Hallucinogenic NBOMes | Q49148401 |
| | Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach | Q49579124 |
| | NBOMe: new potent hallucinogens--pharmacology, analytical methods, toxicities, fatalities: a review | Q26781727 |
| | 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug | Q26822943 |
| | Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature | Q26865329 |
| | Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists | Q28265476 |
| | The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity | Q28281024 |
| | Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex | Q28567004 |
| | Serotonin and Hallucinogens | Q29399981 |
| | LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor | Q30484494 |
| | NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System | Q30969880 |
| | Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36. | Q33851479 |
| | Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor | Q34024760 |
| | Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis | Q34041519 |
| | Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. | Q34144415 |
| | G protein- and agonist-bound serotonin 5-HT2A receptor model activated by steered molecular dynamics simulations | Q34160474 |
| | Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens | Q34167036 |
| | Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents | Q34262666 |
| | 25C-NBOMe--new potent hallucinogenic substance identified on the drug market. | Q34300481 |
| | A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug | Q34331924 |
| | Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series | Q34348317 |
| | Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response | Q34369264 |
| | Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. | Q34396223 |
| | The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample | Q34406732 |
| | Near fatal intoxication with the novel psychoactive substance 25C-NBOMe | Q34417353 |
| | Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. | Q34435965 |
| | "My friend said it was good LSD": a suicide attempt following analytically confirmed 25I-NBOMe ingestion | Q34453002 |
| | N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues | Q34455931 |
| | Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action | Q34485906 |
| | Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). | Q34491433 |
| | Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands | Q34555941 |
| | Analysis of new designer drugs in post-mortem blood using high-resolution mass spectrometry. | Q35536635 |
| | Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper | Q36062676 |
| | Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical Intoxication | Q36062680 |
| | Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats | Q37306537 |
| | Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents. | Q50627353 |
| | Metabolic Profile Determination of NBOMe Compounds Using Human Liver Microsomes and Comparison with Findings in Authentic Human Blood and Urine. | Q50673261 |
| | Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus. | Q50674127 |
| | Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. | Q51166112 |
| | Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). | Q52249429 |
| | Neurotoxicity screening of new psychoactive substances (NPS): Effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA). | Q52639645 |
| | LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening pow | Q52760538 |
| | Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. | Q52867769 |
| | Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH. | Q53063534 |
| | Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. | Q53080749 |
| | A fatal poisoning involving 25C-NBOMe. | Q53555634 |
| | 25C-NBOMe Ingestion. | Q55383928 |
| | Effects of exposure to 5-MeO-DIPT during adolescence on brain neurotransmission and neurotoxicity in adult rats | Q64388191 |
| | Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MS(n), and LC-HR-MS/MS | Q85459796 |
| | NBOMe designer drug exposures reported to Texas poison centers | Q87554122 |
| | Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe | Q87778674 |
| | Drug Recognition Evaluation and Chemical Confirmation of a 25C-NBOMe-Impaired Driver | Q89414093 |
| | In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models | Q89416109 |
| | Nano liquid chromatography-high-resolution mass spectrometry for the identification of metabolites of the two new psychoactive substances N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)-4-methylmethamphetamine | Q90367888 |
| | 5-Methoxy-α-methyltryptamine (5-MeO-AMT), a tryptamine derivative, induces head-twitch responses in mice through the activation of serotonin receptor 2a in the prefrontal cortex | Q90573484 |
| | Mix of new substances psychoactive, NPS, found in blotters sold in two Colombian cities | Q90591689 |
| | Metabolic profile determination of 25N-NBOMe in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry | Q90847102 |
| | Clinical and Toxicological Profile of NBOMes: A Systematic Review | Q90868866 |
| | DARK Classics in Chemical Neuroscience: NBOMes | Q90969018 |
| | 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo | Q91112345 |
| | Gas Chromatography-Mass Spectrometry Method for the Quantitative Identification of 23 New Psychoactive Substances in Blood and Urine | Q91277413 |
| | 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential | Q91364907 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | lysergic acid diethylamide | Q23118 |
| P304 | page(s) | 78 | |
| P577 | publication date | 2020-02-26 | |
| P1433 | published in | Frontiers in Neuroscience | Q2177807 |
| P1476 | title | NBOMes-Highly Potent and Toxic Alternatives of LSD | |
| P478 | volume | 14 | |